User talk:Innerstream

"O-Cresyl glycidyl ether (o-CGE)" listed at Redirects for discussion
An editor has identified a potential problem with the redirect O-Cresyl glycidyl ether (o-CGE) and has thus listed it for discussion. This discussion will occur at Redirects for discussion/Log/2022 April 11 until a consensus is reached, and anyone, including you, is welcome to contribute to the discussion. DMacks (talk) 06:51, 11 April 2022 (UTC)

ArbCom 2022 Elections voter message
 Hello! Voting in the 2022 Arbitration Committee elections is now open until 23:59 (UTC) on. All eligible users are allowed to vote. Users with alternate accounts may only vote once.

The Arbitration Committee is the panel of editors responsible for conducting the Wikipedia arbitration process. It has the authority to impose binding solutions to disputes between editors, primarily for serious conduct disputes the community has been unable to resolve. This includes the authority to impose site bans, topic bans, editing restrictions, and other measures needed to maintain our editing environment. The arbitration policy describes the Committee's roles and responsibilities in greater detail.

If you wish to participate in the 2022 election, please review the candidates and submit your choices on the voting page. If you no longer wish to receive these messages, you may add to your user talk page. MediaWiki message delivery (talk) 01:50, 29 November 2022 (UTC)

I have sent you a note about a page you started
Hello, Innerstream. Thank you for your work on Fipravirimat. User:SunDawn, while examining this page as a part of our page curation process, had the following comments:

To reply, leave a comment here and begin it with. Please remember to sign your reply with ~. (Message delivered via the Page Curation tool, on behalf of the reviewer.)

&maltese; SunDawn &maltese;   (contact)   06:08, 4 February 2023 (UTC)

Ways to improve Resmetiron
Hello, Innerstream,

Thank you for creating Resmetiron.

I have tagged the page as having some issues to fix, as a part of our page curation process and note that:

"Needs more verifiable sources to establish notability"

The tags can be removed by you or another editor once the issues they mention are addressed. If you have questions, leave a comment here and begin it with. Remember to sign your reply with. For broader editing help, please visit the Teahouse.

Delivered via the Page Curation tool, on behalf of the reviewer.

Ppt91 (talk) 00:11, 8 February 2023 (UTC)

Keanumycins
Hi, thanks for the structures of the keanumycins A-C and uploading images of them. Do you happen to have the SMILES or MDL molfiles of the drawings? Btw, what made you decide on the double bond E/Z in the bottom of the drawing? Because when I read the article, they draw it as undefined. Egon Willighagen (talk) 07:26, 5 March 2023 (UTC)


 * It looks like I should have drawn the structures in a way that shows that double bond as having undefined stereochemistry. I'll make the necessary corrections to the images shorty.  Thanks for catching that.  Here are the SMILES for the three compounds (though they still have the stereochem error that you note).

A: CCCCCCCCCCCC[C@@H](O)[C@@H](O)CC(=O)N[C@@H](CO)C(=O)N[C@H](CCN)C(=O)NCC(=O)N[C@H](CCO)C(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@H](C)O)C(=O)N\C(=C/C)C(=O)N[C@@H]([C@H](O)C(O)=O)C(=O)N[C@@H]([C@H](O)CCl)C(O)=O B: CCCCCCCCCCCCC[C@@H](O)CC(=O)N[C@@H](CO)C(=O)N[C@H](CCN)C(=O)NCC(=O)N[C@H](CCO)C(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@H](C)O)C(=O)N\C(=C/C)C(=O)N[C@@H]([C@H](O)C(O)=O)C(=O)N[C@@H]([C@H](O)CCl)C(O)=O C: CCCCCCCCCCCC[C@@H](O)[C@@H](O)CC(=O)N[C@@H](CO)C(=O)N[C@H](CC=N)C(=O)NCC(=O)N[C@H](CCO)C(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@H](C)O)C(=O)N\C(=C/C)C(=O)N[C@@H]([C@H](O)C(O)=O)C(=O)N[C@@H]([C@H](O)CCl)C(O)=O


 * Innerstream (talk) 14:20, 7 March 2023 (UTC)


 * I have now updated the three images. Innerstream (talk) 14:57, 12 March 2023 (UTC)

Really?
Re: NaOTs and NaO3SPh. What is now depicted is harmless, and such representations will appeal to general readers. The components would separate upon solvation with water, etc. But the article is not about solvates. True, Na+ is often naked.... inside a mass spectrometer.--Smokefoot (talk) 20:12, 18 March 2023 (UTC)
 * Any time one is depicting the structure of a chemical compound as a two-dimensional line drawing, some details of structure are not going to be conveyed easily. Therefore certain conventions have evolved so that the depictions are understood the same way by different individuals.  If you would like to go by what will "appeal to general readers", I think the depiction of a sodium sulfonate as an anion/cation pair will be the most well understood because it is consistent with standard convention.  For example, look at the hundreds of files in w:commons:Category:Sodium sulfonates and its subcategories.  You would be hard pressed to find any example of a sodium sulfonate depicted with a solid line between oxygen and sodium, which by convention indicates a fully covalent bond. However, if you feel strongly that the original images in those two articles are better, I won't object if you restore them.  Also, I removed the disputed template for those images because that template seem best suited for uncontested situations.  Innerstream (talk) 21:04, 18 March 2023 (UTC)
 * Thanks for taking the time to write a response. No big deal.  I confess to be slightly preoccupied by non-nakedness of ions, and very sick of people drawing computer images that show naked little spheres for ions.  But you are probably correct about conventions as well as the compromises we all make with drawings.  --Smokefoot (talk) 23:13, 18 March 2023 (UTC)

Lysine acetylsalicylate
Thanks for the drugbox! The image of the lysine component is missing a carbon in its side-chain. DMacks (talk) 20:42, 8 June 2023 (UTC)
 * Thanks for catching that. Since you're a Commons administrator, can you please delete File:Lysine acetylsalicylate.svg and File:Lysine acetylsalicylate v2.svg.  They are both incorrect and there is already a correct alternative.   Innerstream (talk) 12:54, 9 June 2023 (UTC)
 * Done. DMacks (talk) 14:17, 10 June 2023 (UTC)

I have sent you a note about a page you started
Hello, Innerstream. Thank you for your work on Simnotrelvir/ritonavir. User:SunDawn, while examining this page as a part of our page curation process, had the following comments:

To reply, leave a comment here and begin it with. Please remember to sign your reply with ~. (Message delivered via the Page Curation tool, on behalf of the reviewer.)

&maltese; SunDawn &maltese;   (contact)   03:40, 9 October 2023 (UTC)

ArbCom 2023 Elections voter message
 Hello! Voting in the 2023 Arbitration Committee elections is now open until 23:59 (UTC) on. All eligible users are allowed to vote. Users with alternate accounts may only vote once.

The Arbitration Committee is the panel of editors responsible for conducting the Wikipedia arbitration process. It has the authority to impose binding solutions to disputes between editors, primarily for serious conduct disputes the community has been unable to resolve. This includes the authority to impose site bans, topic bans, editing restrictions, and other measures needed to maintain our editing environment. The arbitration policy describes the Committee's roles and responsibilities in greater detail.

If you wish to participate in the 2023 election, please review the candidates and submit your choices on the voting page. If you no longer wish to receive these messages, you may add to your user talk page. MediaWiki message delivery (talk) 00:55, 28 November 2023 (UTC)

A Nanokid for you!

 * Cute kid. Thank you!  Innerstream (talk) 23:42, 13 January 2024 (UTC)

Hey
I noticed that you've been editing some health-related articles recently. A bunch of us hang out at Wikipedia talk:WikiProject Medicine. It's a good place to ask questions about good sources for medical content and appropriate writing style. There's also a much smaller group at Wikipedia talk:WikiProject Veterinary medicine. Please consider putting the page on your watchlist, or stop by to say hello some time. WhatamIdoing (talk) 19:07, 16 January 2024 (UTC)
 * Thanks for the suggestion. I'll watchlist those pages.  Innerstream (talk) 02:32, 17 January 2024 (UTC)
 * Thanks! WhatamIdoing (talk) 02:35, 17 January 2024 (UTC)

I have sent you a note about a page you started
Hello, Innerstream. Thank you for your work on Sulanemadlin. Klbrain, while examining this page as a part of our page curation process, had the following comments:

To reply, leave a comment here and begin it with. Please remember to sign your reply with ~. (Message delivered via the Page Curation tool, on behalf of the reviewer.)

Klbrain (talk) 16:52, 18 April 2024 (UTC)

I have sent you a note about a page you started
Hi Innerstream. Thank you for your work on Hyzetimibe. Another editor, Klbrain, has reviewed it as part of new pages patrol and left the following comment:

To reply, leave a comment here and begin it with. (Message delivered via the Page Curation tool, on behalf of the reviewer.)

Klbrain (talk) 13:30, 24 April 2024 (UTC)
 * Thanks for reviewing the articles I recently created. In the template Infobox drug, the "CAS_number" field links to the Common Chemistry website, which consists of only a small subset of all CAS numbers and therefore it is not a good source for verification of CAS numbers. I have verified this particular CAS number (and all other CAS numbers I have added) directly with the Chemical Abstracts Service database itself.  Innerstream (talk) 18:20, 24 April 2024 (UTC)
 * Thanks for checking, and for letting me know about the unreliability of the Common Chemistry website for checking CAS numbers! Klbrain (talk) 20:25, 24 April 2024 (UTC)

I have sent you a note about a page you started
Hi Innerstream. Thank you for your work on Surufatinib. Another editor, Klbrain, has reviewed it as part of new pages patrol and left the following comment:

To reply, leave a comment here and begin it with. (Message delivered via the Page Curation tool, on behalf of the reviewer.)

Klbrain (talk) 13:33, 24 April 2024 (UTC)

I have sent you a note about a page you started
Hi Innerstream. Thank you for your work on Orelabrutinib. Another editor, Klbrain, has reviewed it as part of new pages patrol and left the following comment:

To reply, leave a comment here and begin it with. (Message delivered via the Page Curation tool, on behalf of the reviewer.)

Klbrain (talk) 13:36, 24 April 2024 (UTC)

I have sent you a note about a page you started
Hi Innerstream. Thank you for your work on Hetrombopag. Another editor, Klbrain, has reviewed it as part of new pages patrol and left the following comment:

To reply, leave a comment here and begin it with. (Message delivered via the Page Curation tool, on behalf of the reviewer.)

Klbrain (talk) 10:30, 6 May 2024 (UTC)
 * Are you sure hetrombopag is the INN? The FDA seems to think the INN is rafutrombopag. If you click on the UNII link in the infobox, it takes you to a FDA webpage for the drug (https://precision.fda.gov/uniisearch/srs/unii/9WGT51BDDL) with the synonym "RAFUTROMBOPAG [INN]". Can you have a second look?  Thanks.  Innerstream (talk) 13:55, 6 May 2024 (UTC)
 * Interesting; IUPHAR, which sticks to INN, uses hetrombopag, and given that the peer-reviewed sources are using it too ... USFDA uses UNII names, which aren't necessarily INNs. Klbrain (talk) 18:56, 6 May 2024 (UTC)
 * I bet this is a case where the generic name has been changed during the course of drug development and/or different naming organizations have settled on different names. But I suppose the article is fine titled either way, with the appropriate redirects.  Cheers,  Innerstream (talk) 19:58, 6 May 2024 (UTC)

I have sent you a note about a page you started
Hi Innerstream. Thank you for your work on Disitamab vedotin. Another editor, Klbrain, has reviewed it as part of new pages patrol and left the following comment:

To reply, leave a comment here and begin it with. (Message delivered via the Page Curation tool, on behalf of the reviewer.)

Klbrain (talk) 19:22, 19 July 2024 (UTC)